CALT - Calliditas Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

454.1M

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

0.03%

Insider Ownership

0.00%

Institutional Own.

3.57%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Setanaxib (NOX1/NOX4 inhibitor) Details Primary biliary cholangitis, Liver disease	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Setanaxib (NOX1/NOX4 inhibitor) Details Solid tumor/s, Cancer, Head and neck squamous cell carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Setanaxib (NOX1/NOX4 inhibitor) Details Alport Syndrome	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.